Docetaxel-Loaded Methoxy poly(ethylene glycol)-poly (L-lactic Acid) Nanoparticles for Breast Cancer: Synthesis,...

Area of Science:

• Nanotechnology
• Pharmaceutical Sciences
• Biomedical Engineering

Background:

• Docetaxel (DTX) is a key chemotherapy agent for breast cancer (BC).
• Developing effective drug delivery systems for DTX is crucial for improving therapeutic efficacy and reducing side effects.
• Polymeric nanoparticles offer a promising platform for targeted drug delivery and controlled release.

Purpose of the Study:

• To synthesize and characterize docetaxel-loaded mPEG-PLA nanoparticles (DTX-mPEG-PLA-NPs).
• To develop and validate a reliable analytical method for quantifying DTX within the nanoparticles.
• To evaluate the in vitro cytotoxicity and anti-clonogenic effects of DTX-mPEG-PLA-NPs on breast cancer cell lines.

Main Methods:

• Nanoparticle characterization using Atomic Force Microscopy (AFM), Dynamic Light Scattering (DLS), and zetasizer.
• Development and validation of a Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) assay for DTX quantification.
• In vitro cytotoxicity assessment using MTT assays and anti-clonogenic assays on MCF-7 and MDA-MB-231 cell lines in 2D and 3D cultures.

Main Results:

• DTX-mPEG-PLA-NPs showed an average particle size of 264.3 nm and 62.22% encapsulation efficiency.
• The RP-HPLC method demonstrated linearity, high precision (RSD ≤2%), and accuracy, meeting ICH guidelines.
• In vitro studies revealed enhanced cytotoxicity and significant inhibition of clonogenic potential, particularly in 3D mammosphere cultures.

Conclusions:

• The developed RP-HPLC method is robust and suitable for DTX quantification in nanoparticles.
• DTX-mPEG-PLA-NPs serve as an effective and biocompatible delivery vehicle.
• These nanoparticles exhibit enhanced cytotoxic and anti-clonogenic properties, suggesting potential for improved breast cancer therapy.